MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Juno Biomedical Inc., a startup developing a revolutionary technology to repair damaged brain tissue in stroke victims, was selected by Singularity University to participate in their highly selective SU Labs Startup Accelerator program. The program, which kicked-off last week, only selects startups using cutting-edge technologies to solve humanity’s grand challenges.
With its mission to improve quality of life for patients after neurological damage, Juno Biomedical joined other pioneering startups in Silicon Valley last week. CEO Trisha Pfluger expects that the accelerator will facilitate the development of Juno Biomedical’s long-term strategy and improve its access to capital.
“Singularity University’s program is the only accelerator where your homework is to better the lives of at least 1 billion people worldwide,” Pfluger says, adding: “The program gives us uncommon access to a new network of resources and connections -- we’ve already been introduced to a number of venture capitalists, innovators and industry leaders.”
Juno Biomedical’s technology, developed in part at UC Davis, could change the standard of care for survivors of stroke and brain injury. With more than 30 million stroke survivors worldwide there is a substantial need for their technology. With no current treatment to repair brain tissue damage, stroke survivors must adapt to their disability. Juno Biomedical’s CELLTech™ technology is intended to heal brain tissue damage by facilitating new neural connections between functional cells and has been shown in pre-clinical trials to be safe and effective. This revolutionary technology could return stroke and brain injury patients who currently have no other options to a state of well-being.
About Juno Biomedical, Inc.
Juno Biomedical was launched in 2014 in Davis, CA by scientist and inventor Trisha Pfluger with an aim to transform the standard of care for persons with neurological impairment. Founded on the idea that patient care should heal the underlying cause of disease rather than only alleviate the symptoms, Juno Biomedical endeavors to integrate technologies such as digital patient monitoring, bioelectric therapy, and tissue regeneration to create an innovative medical device that can heal brain tissue damage. Now headquartered in Mountain View, CA, the company is pioneering advances not only in healing, but in personalized, in-home medical care. For further information, visit JunoBiomedical.com.
